Postdoctoral Research Scientist
I joined the Oxford Drug Discovery Institute in collaboration with the Wade-Martins’ lab in 2018 as a Postdoctoral Research Scientist. My research targets the Ubiquitination pathway in Parkinson’s Disease (PD) and currently I am using biochemical and biophysical approaches to investigate and identify potential new selective deubiquitinating enzyme inhibitor compounds as a therapeutically treatment of PD.
I gained my scientific background in Molecular Cell Biology and Molecular Medicine at the University of Erlangen-Nuremberg, where I obtained my B.Sc. and M.Sc. degree and then completed a PhD in Neurophysiology in collaboration with King`s College London.
For my doctoral studies, I investigated sensory transduction mechanisms and their importance for nociception and pain on TRP channels. In particular, I investigated the role of the ion-channel TRPA1 in diabetic neuropathy as well as targeting TRPA1 for drug discovery using a wide range of techniques including patch clamp electrophysiology and Ca2+ imaging.
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
O’Brien DP. et al, (2022)
USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation
Rusilowicz-Jones EV. et al, (2020), Life Science Alliance, 3, e202000768 - e202000768
Pre- and postoperative headache in patients with meningioma
Guenther F. et al, (2019), Cephalalgia, 39, 533 - 543
Impaired Nociception in the Diabetic Ins2+/Akita Mouse
Vastani N. et al, (2018), Diabetes, 67, 1650 - 1662
Complex reinnervation pattern after unilateral renal denervation in rats
Rodionova K. et al, (2016), American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 310, R806 - R818